Want to read this magazine in your preferred language? You can translate the entire document using any modern AI tool (such as Gemini, ChatGPT, or Claude). Just follow these simple steps:
A glimpse to new clinical studies to find the causes for ASD
Ram Kamal
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition defined by persistent challenges in social communication, language development, and the presence of restricted or repetitive behaviors. Over the last half-century, the reported global incidence of ASD has surged more than 100-fold.
As of 2020, data from the United States indicates a prevalence of 1 in 36 children, with a notable male-to-female ratio of approximately 3.8:1 to 4:1. In India, in a recent study conducted in Telengana and Andhra Pradesh confirm it as 1 in 68 children. While the rise in prevalence is partly attributed to better awareness and diagnostic criteria, contemporary scientific research increasingly views ASD as the result of an intricate interaction between genetic susceptibility and early-life environmental influences.
Genetic factors provide the foundation for ASD susceptibility through gene mutations, copy number variations (CNVs), and epigenetic modifications. Research has identified specific monogenic syndromes where ASD is a primary feature, such as Fragile X syndrome (FMR1), Rett syndrome (MECP2), and Tuberous Sclerosis (TSC1/TSC2). These mutations disrupt fundamental processes including neuronal migration, synaptic structure, and neurotransmitter release.
The Simons Foundation Autism Research Initiative (SFARI) currently tracks 1,231 ASD risk genes, assigning evidence-based scores to each. However, because approximately 75ā80% of individuals with ASD lack a clear single-gene mutation, researchers have turned toward models of convergent coexpression. This concept suggests that many diverse risk genes actually converge on shared molecular pathways during brain development. Postmortem studies of ASD brain tissue reveal a consistent downregulation of genes related to synaptic function and an upregulation of genes associated with glial cells and immune responses.
A critical genetic phenomenon is the "Female Protective Effect," which helps explain the gender disparity in ASD. Evidence suggests that females may possess a higher biological tolerance for genetic mutations, requiring a greater "genetic burden"āsuch as more functional de novo mutations or pathogenic mitochondrial DNA (mtDNA) mutationsāto reach the diagnostic threshold for ASD.
While genetics provide the substrate, early-life environmental exposures act as triggers that can exacerbate genetic vulnerabilities.
Advanced maternal age (ā„40) and paternal age (ā„50) are recognized as independent risk factors. This risk is mediated through two primary channels:
Gestational and pregestational diabetes have emerged as major environmental drivers. Earlier maternal hyperglycemia (diagnosed before 26 weeks) is specifically associated with an increased risk of ASD in offspring. High glucose levels in utero can induce oxidative stress and the continuous generation of reactive oxygen species (ROS) in fetal neuronal cells. Furthermore, maternal diabetes can lead to the hypomethylation of ASD-linked genes, such as OR2L13, in newborns.
The intrauterine hormonal environment is crucial for brain development. Elevated levels of androgens, progesterone, and estradiol in amniotic fluid are associated with subsequent ASD diagnoses. Women with Polycystic Ovary Syndrome (PCOS) have a higher risk of having children with ASD due to these hormonal imbalances. Specifically, high levels of progestins can cause epigenetic silencing (methylation) of the estrogen receptor Ī (ERĪ) promoter in the offspring's brain, leading to suppressed expression of protective antioxidant and metabolic genes.
Exposure to pollutants during pregnancy, including PM 2.5 air pollution, heavy metals (lead, cadmium, mercury), and pesticides like glyphosate-based herbicides, has been linked to heightened ASD risk. These pollutants can cross the placenta and, due to the fetus's underdeveloped blood-brain barrier, significantly disrupt neuronal migration and lipid metabolism. For example, automobile exhaust exposure has been shown to alter DNA hydroxymethylation of genes required for proper neuronal migration.
The "bridge" between genetic risk and environmental triggers is primarily built through epigenetic modifications. These changes alter gene expression without changing the DNA sequence itself, often occurring in response to environmental stressors.
A core convergent pathway in ASD is mitochondrial dysfunction. Both genetic mutations and environmental factors (like maternal hyperglycemia) can damage mitochondria, causing them to release mtDNA. This released DNA acts as a damage-associated molecular pattern (DAMP), which initiates neuroinflammation and persistent oxidative stress, ultimately leading to ASD-like phenotypes.
Many environmental factorsāincluding infections and pollutantsāactivate the maternal immune system and induce oxidative stress. This stress pathway is also regulated by many ASD risk genes, meaning environmental triggers can "double-hit" a pre-existing genetic vulnerability.
The deepening understanding of these interactions has shifted research toward targeted pharmacological interventions that address biological root causes.
Resveratrol, a natural antioxidant, is being investigated for its ability to cross the blood-brain barrier and activate the ERĪ pathway. In animal models, resveratrol has been shown to:
Peroxisome proliferator-activated receptor (PPAR) agonists, specifically pioglitazone, are experimental therapies that target neuroinflammation and mitochondrial energy metabolism. In rat models, pioglitazone has shown success in improving social communication deficits and stereotyped behaviors. This neuroprotective effect is linked to the drug's ability to modulate the Wnt/beta-catenin pathway, which is vital for neuronal survival.
The future of diagnosis is moving toward a multi-dimensional approach. This involves combining digital biomarkers (eye-tracking, neuroimaging classifiers, AI-driven behavioral analysis) with biological biomarkers (inflammatory cytokines, miRNA profiles like miR-451a, and gut microbiota characteristics). Comprehensive models, such as those integrating 31 multi-kingdom gut microbiota markers, have achieved diagnostic accuracy rates (ROC) as high as 0.91.
Current research underscores that ASD is rarely caused by a single factor but rather a multifactorial risk model where environmental stressors disrupt neuronal and synaptic functions during critical windows of development, acting upon a backdrop of genetic susceptibility. Epigenetic modifications serve as the functional mechanism through which these factors converge to induce mitochondrial dysfunction, neuroinflammation, and oxidative stress.
While many treatmentsāsuch as PPAR agonists and small molecule therapiesāremain in the experimental phase, they represent a significant move toward individualized ASD therapy grounded in etiology. Addressing ASD as a multifaceted global health challenge requires continued integration of genetic research, environmental monitoring, and the development of molecular diagnostics to enable earlier and more effective intervention.